Thyroid gland follicular carcinoma
MONDO:0005034A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland. The nuclear features which characterize the thyroid gland papillary carcinoma are absent. Radiation exposure is a risk factor and it comprises approximately 10% to 15% of thyroid cancers. Clinically, it usually presents as a solitary mass in the thyroid gland. It is generally unifocal and thickly encapsulated and shows invasion of the capsule or the vessels. Diagnostic procedures include thyroid ultrasound and fine needle biopsy.
Also known as: follicular cancer of the thyroid, follicular cancer of the thyroid gland, follicular cancer of thyroid, follicular cancer of thyroid gland, thyroid gland follicular cancer, well-differentiated follicular carcinoma, carcinoma of thyroid follicle, carcinoma, follicular cell, malignant
2830 clinical trials for this condition and its sub-types, 20 tagged with Thyroid gland follicular carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Thyroid gland follicular carcinoma
-
Medullary thyroid gland carcinoma 42 trials · 53 incl. sub-types
1 sub-type
- Familial medullary thyroid carcinoma 23 trials
-
Thyroid Hurthle cell carcinoma 11 trials
-
Thyroid cancer, nonmedullary, 2 4 trials
-
Thyroid cancer, nonmedullary, 4 0 trials
-
Thyroid cancer, nonmedullary, 5 0 trials
-
Trabecular follicular adenocarcinoma 0 trials
-
New hope for Hard-to-Treat thyroid cancer: drug XL092 enters human trials
Disease control Recruiting nowThis phase 2 trial tests a drug called XL092 in 33 people with advanced thyroid cancer that has stopped responding to radioiodine therapy. XL092 works by blocking a protein that helps cancer cells grow. The study aims to see if the drug can slow or stop cancer progression.
Phase 2 • Sponsor: Jochen Lorch • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Drug cocktail may help radioactive iodine work better in tough thyroid cancers
Disease control Recruiting nowThis phase 2 trial tests whether two targeted drugs, vemurafenib and cobimetinib, can make thyroid cancer cells more responsive to radioactive iodine therapy. The study enrolls 21 adults with high-risk, BRAF-mutated thyroid cancer who have not yet received radioactive iodine. Par…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New Alpha-Particle drug targets Hard-to-Treat thyroid cancer
Disease control Recruiting nowThis early-stage trial tests a new radioactive drug called Af-001 in people with advanced differentiated thyroid cancer that cannot be removed by surgery or has spread. The study has two parts: first, to find the safest dose, and second, to see if multiple doses can shrink tumors…
Phase 1 • Sponsor: Alpha Fusion Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New scan could spot hidden thyroid cancer better
Diagnosis Recruiting nowThis study is testing a new type of PET/CT scan (18F-TFB) to see if it can find thyroid cancer that has come back or spread better than the current standard scan. About 24 adults with papillary or follicular thyroid cancer will get both scans to compare results. The goal is to im…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
Coaching boosts thyroid cancer recovery
Symptom relief Recruiting nowThis study tests if health and wellness coaching helps people with papillary or follicular thyroid cancer follow their treatment plans and live healthier lives. Twenty adults who have had their thyroid removed and take daily thyroid medication will work with a coach to set goals …
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
Massive study aims to unlock secrets of thyroid nodules and cancer
Knowledge-focused Recruiting nowThis study is for people who have or might have a thyroid nodule or thyroid cancer. Researchers want to learn more about how to diagnose and treat these conditions. Participants will have standard medical tests like blood draws and scans, plus some extra research tests. The goal …
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC